Neurology & Brain Disorders Clinical Trials Update: Week 13, 2026

Published March 29, 2026 — 5 trials covered

By Victor Lafforgue, Founder of TrialsAlert. Blog posts are AI-drafted from ClinicalTrials.gov source data and reviewed by the editorial team. See our editorial policy for details.

A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus)

This large Phase 3 study tested the oral drug semaglutide in 1840 people with early Alzheimer's disease across many countries. The goal was to see if semaglutide could slow down memory and thinking problems. If the results show it works, semaglutide may become a new, easier-to-take treatment option that could improve daily life for people in the early stages of Alzheimer's.

China Cognition and Aging Study

This ongoing study in China focuses on people with mild cognitive impairment and Alzheimer's disease. It aims to understand what causes these conditions and find effective non-drug treatments to slow cognitive decline. By following participants long-term at 65 locations, the study hopes to improve how these conditions are diagnosed and managed in the future.

A Dyadic Sleep Intervention for Alzheimer's Disease Patients and Their Caregivers

This study tested a behavioral program to help both Alzheimer's patients and their caregivers improve sleep. Since poor sleep is common and challenging for both groups, improving it could greatly enhance their quality of life. The trial completed with 60 participants in the United States, and the results will help shape supportive care strategies.

Brain Effects of Gamma Frequency Sensory Stimulation (40Hz Light, Sound and Other Devices)

This Phase 2 trial is exploring a new non-invasive approach using light and sound stimulation called GENUS. It involves a short visit with brain imaging to study its effects on cognitively healthy adults and people with Alzheimer's disease. If successful, this gentle sensory stimulation could offer a novel way to slow cognitive decline and support brain health.

The Chinese Familial Alzheimer's Network

This large study is recruiting up to 40,000 participants across China to better understand familial Alzheimer's disease, an inherited form of the condition. By studying its genetics and progression, researchers aim to improve diagnosis and care for families affected by this form of Alzheimer's. This work could lead to more personalized approaches to treatment in the future.

TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.